T. Rowe Price Associates
ERNA icon

T. Rowe Price Associates’s Eterna Therapeutics ERNA Stock Holding History

T. Rowe Price Associates’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3
Closed -$191K – 3000
2021
Q3 		$191K Buy
+3
New +$259K ﹤0.01% 2738

Other funds holding ERNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CPWM
Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Inverness Counsel New York $1.8B AUM 9.9% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates's ERNA Position: Q4 2021 in Review

T. Rowe Price Associates sold out of Eterna Therapeutics (ERNA) in Q4 2021, closing a stake of 3 shares — an estimated $191K sold.

T. Rowe Price Associates first reported a position in ERNA in Q3 2021 and held it in 1 quarter. The position peaked at $191K in Q3 2021. 47 funds tracked by Wall St. Rank hold ERNA as of Q4 2021.

  • T. Rowe Price Associates reported no remaining Eterna Therapeutics position as of Q4 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 3 Eterna Therapeutics shares in Q4 2021, an estimated $191K.
  • T. Rowe Price Associates first reported a position in Eterna Therapeutics in Q3 2021 and held it in 1 quarter.
  • T. Rowe Price Associates's Eterna Therapeutics position peaked at $191K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q4 2021.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.